| Psoriasis vulgaris
Sotyktu vs Vtama
Side-by-side clinical, coverage, and cost comparison for psoriasis vulgaris.Deep comparison between: Sotyktu vs Vtama with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVtama has a higher rate of injection site reactions vs Sotyktu based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Vtama but not Sotyktu, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Sotyktu
Vtama
At A Glance
Oral
Daily
TYK2 inhibitor
Topical
Daily
AhR agonist
Indications
- Psoriasis vulgaris
- Arthritis, Psoriatic
- Psoriasis vulgaris
- Dermatitis, Atopic
Dosing
Psoriasis vulgaris, Arthritis, Psoriatic 6 mg orally once daily, with or without food; do not crush, cut, or chew tablets; not recommended in severe hepatic impairment (Child-Pugh C).
Psoriasis vulgaris, Dermatitis, Atopic Apply a thin layer to affected areas once daily; wash hands after application unless VTAMA cream is for treatment of the hands; not for oral, ophthalmic, or intravaginal use.
Contraindications
- History of hypersensitivity reaction to deucravacitinib or any excipient in SOTYKTU
—
Adverse Reactions
Most common (>=1%) Upper respiratory infections, blood creatine phosphokinase increased, herpes simplex, mouth ulcers, folliculitis, acne
Serious Pneumonia, COVID-19, malignancies including breast cancer, hepatocellular carcinoma, and lymphoma
Most common (>=1%) - Plaque Psoriasis Folliculitis, nasopharyngitis, contact dermatitis, headache, pruritus, influenza
Most common (>=1%) - Atopic Dermatitis Upper respiratory tract infection, folliculitis, lower respiratory tract infection, headache, asthma, vomiting, ear infection, pain in extremity, abdominal pain
Pharmacology
TYK2 inhibitor; deucravacitinib binds the regulatory domain of TYK2, allosterically inhibiting receptor-mediated TYK2 activation and downstream STAT signaling via the JAK-STAT pathway.
Tapinarof is an aryl hydrocarbon receptor (AhR) agonist; the specific mechanisms by which VTAMA cream exerts its therapeutic actions in plaque psoriasis and atopic dermatitis are unknown.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Sotyktu
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Vtama
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Sotyktu
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (6/8) · Qty limit (6/8)
Vtama
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (4/8) · Qty limit (4/8)
Humana
Sotyktu
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Vtama
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Psoriasis
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Final cost depends on formulary coverage
Cost estimate not availableAssistance Fund: Psoriasis
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Final cost depends on formulary coverage
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
SotyktuView full Sotyktu profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.